Clinical Study
Factors Associated with Inadequate Tissue Yield in EUS-FNA for Gastric SMT

Takuto Suzuki, Makoto Arai, Tomoaki Matsumura, Eiji Arai, Sachio Hata, Daisuke Maruoka, Takeshi Tanaka, Shingo Nakamoto, Fumio Imazeki, and Osamu Yokosuka

Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba 260-8670, Japan

Correspondence should be addressed to Makoto Arai, araim-cib@umin.ac.jp

Received 18 April 2011; Accepted 2 May 2011

Aims. Our aim was to identify the factors that made the specimens inadequate and nondiagnostic in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsy of suspected submucosal tumors (SMTs).

Methods. From August 2001 to October 2009, 47 consecutive patients with subepithelial hypoechoic tumors originating in the fourth sonographic layer of the gastric wall suspected as GIST by standard EUS in Chiba University hospital underwent EUS-FNA for histologic diagnosis. We evaluated patient age, sex, location of lesion, size, pattern of growth in a stomach, and pattern of echography retrospectively. We defined a case of gaining no material or an insufficient material for immunohistological diagnosis as nondiagnostic.

Results. The diagnostic yield of EUS-FNA for the diagnosis of gastric SMTs was 74.5%. Multivariate logistic regression analysis identified that age of under 60 years (compared with patients older than 60 years: odds ratio [OR] = 11.91, 95% confidence interval [CI] = 1.761–80.48) and location of SMT at lower third area (compared with upper or middle third area: OR = 10.62, 95% CI = 1.290–87.42) were the predictive factors for inadequate tissue yield in EUS-FNA.

Conclusions. The factors associated with inadequate tissue yield in EUS-FNA were younger age and the location of lesion at lower third area in stomach.

1. Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. GISTs are frequently discovered by chance on endoscopy performed and are characterized by a bulging of the GI wall with normal, overlying mucosa. GISTs were described in 1983 as tumors in the GI tract and mesentery, characterized by a specific histological and immunohistochemical pattern [1]. Since GIST is now considered as potentially malignant, all GISTs may need to be resected, even small lesions [2]. Differentiating these lesions from benign submucosal lesions such as leiomyomas or schwannomas is crucial. But standard endoscopic biopsy specimens are usually nondiagnostic because the mucosa overlying the submucosal lesion such as GIST is normal.

Endoscopic ultrasonography (EUS), enabling intramural scanning of the GI tract, has been reported to be useful in the diagnosis of submucosal tumor (SMT) and in differentiating SMT from extraluminal lesions [3–5]. EUS is not only capable of characterizing lesions of the GI tract and adjacent structures, but it is also capable of guiding the fine-needle aspiration under real-time ultrasound using a through-the-scope needle aspiration system [6, 7].

Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) is considered to be a reliable and accurate method for the evaluation of submucosal lesions in the GI tract. With this method, it has been reported that the accuracy in gastrointestinal diseases such as SMT was high (38–100%), compared to conventional EUS and that complications including bleeding and infection were rare (0–2.6%) [8, 9].

Therefore, SMT is a suitable target of EUS-FNA. EUS-FNA has been well documented as providing cytologic material for the diagnosis of malignancy, but large studies assessing its utility have mainly looked at its use in sampling lymph nodes, pancreas, and extraintestinal masses [10–16]. Although studies to date evaluating the diagnostic...
yield of EUS-FNA for the diagnosis of GISTs have been reported, those studies analyzed a small number of patients or discussed about general GI tract other than stomach [17–25]. In addition, there were few studies about factors or discussed about general GI tract other than stomach reported, those studies analyzed a small number of patients

The aim of this study was to determine the diagnostic yield of EUS-FNA of suspected GISTs in the stomach and the factors that made specimens inadequate and nondiagnostic.

2. Patients and Methods

2.1. Patients. When we could not obtain tissue from SMTs by the usual endoscopic biopsy, we conducted EUS-FNA. From August 2001 to October 2009, 47 consecutive patients with submucosal hypoechocic tumors originating in the fourth sonographic layer of the gastric wall suspected as GIST by standard EUS underwent EUS-FNA for histologic diagnosis at Chiba University Hospital. This study was carried out only at one institute, the Chiba University Hospital, and was approved by the committee of Chiba University ethical. There were 24 males and 23 females, and the mean age was 60.4 years (range 39–81 years).

2.2. EUS-FNA. Standard EUS was performed using 12 or 15 MHz ultrasound catheter probe SP-701 (FUJIFILM, Japan). The cases diagnosed as lipoma or cyst by EUS were excluded. EUS-FNA was performed on outpatients having SMT-suspected GIST (>2 cm or if <2 cm, increasing in size), with the patient under conscious sedation (Flunitrazepam, 0.4–1.0 mg i.v.), using a conventional convex scanner echoendoscope. This procedure was performed by three endosonographers. The echoendoscope was connected to an ultrasound scanner ProSound SSD-4000 (ALOKA, Japan). The equipment used consisted of GF-UC240P scope (Olympus, Japan) and 22G NA-200H aspiration needles (Wilson-Cook, USA). Color flow and the Doppler sonography were performed to exclude intervening vascular structures and to select a vessel-free needle track to avoid puncturing vessels. After puncture, the inner needle was pulled out. With the vacuum pressure maintained using the connected 20 mL syringe, the aspiration needle was moved within each tumor in various directions more than 10 times. The saline-containing aspirated material was transferred to a Petri dish, and examined macroscopically.

2.3. Immunohistochemistry. Immunoperoxidase stains were subsequently performed on the cell block and representative histologic sections of the tumor using commercially available antibodies against c-kit (CD117), CD34, S-100, and smooth-muscle actin. Diagnosis of GIST was made when pathologic examination showed spindle or epithelioid cells that stained positive for c-kit.

2.4. Factors Associated with Inadequate Tissue in EUS-FNA. We defined a case of gaining a sufficient material for immunohistological diagnosis as diagnostic and calculated a diagnostic yield. We divided patients into two groups, diagnostic and nondiagnostic group and evaluated patient age, sex, location of lesion, size long axis (in millimeters), pattern of growth in stomach, and pattern of echography. As for the gastric neoplasm group, the location of the lesion in stomach was classified into three areas: upper third (U), middle third (M), and lower third (L).

2.5. Ethics. This study was carried out only at one institute, Chiba University Hospital and was approved by the committee of Chiba University ethical. Written informed consent was obtained from all the patients in accordance with the Declaration of Helsinki.

2.6. Statistical Analysis. Data are shown as the mean ± SD. The difference between two groups was tested by the Student’s t-test. Comparisons of proportions were performed using the chi-square test. P < .05 was considered statistically significant. To evaluate the clinical parameters for inadequate tissue yield in EUS-FNA for gastric SMT, logistic regression analysis was performed. SPSS software version 16.0 (SPSS Inc., Chicago, Ill, USA) was used for statistical analysis.

3. Results

3.1. Patients and the Results of EUS-FNA. A total of 47 patients who had undergone EUS-FNA of gastric fourth layer subepithelial lesions were identified. The mean age of patients was 60.4. Of the total of 47 cases, 35 (74.5%) had adequate FNA materials for cytological and histological
examination. And 12 (25.5%) were judged as inadequate. The diagnostic yield was 74.5%. Figure 1 shows the location in the stomach (anterior wall, posterior wall, greater curvature, and lesser curvature) of each case (Figure 1). Final diagnoses after EUS-FNA were GIST ($n = 27$), leiomyoma ($n = 2$), schwannoma ($n = 1$), aberrant pancreas ($n = 2$), malignant lymphoma ($n = 1$), adenocarcinoma ($n = 1$), inflammatory granuloma ($n = 1$), and nondiagnostic ($n = 12$). Surgical resection in our hospital was performed in 13 of 27 patients that were diagnosed having GIST in EUS-FNA. To compare the pathologic findings in the tissues from EUS-FNA with the specimen obtained from surgical resection, the accuracy was 100%. No complications occurred (Table 1). EUS-FNA with immunohistochemical analysis was a safe and accurate method in the pretherapeutic diagnosis of SMT. A case with adequate specimen obtained from EUS-FNA was shown in Figure 2.

3.2. Factors Associated with Inadequate Tissue Yield. There were 35 patients with diagnostic FNA cytologic findings and on the other hand, 12 patients without diagnostic cytologic findings. The clinical background of the patients was shown in Table 2. There was no statistical significance in sex, size, pattern of growth in the stomach, and pattern of echography in the patients with and without diagnostic cytological finding. On the other hand, the diagnostic yield of EUS-FNA cytology for the diagnosis of SMT was influenced by age and location. Patients were significantly younger in the nondiagnostic group, with a mean age of 49.0 compared with 64.4. The lesions significantly located in L area more than U or M area in the nondiagnostic group (Table 2). The thresholds of age and size of SMT were the average value in the patients. Univariate analysis identified that age of under 60 years and location of SMT at L area were independent factors for inadequate tissue yield in EUS-FNA. Multivariate logistic regression analysis identified that age of under 60 years (compared with patients older than 60 years: odds ratio (OR) = 11.91, 95% confidence interval (CI) = 1.761–80.48) and location of SMT at L area (compared with U or M area: OR = 10.62, 95% CI = 1.290–87.42) were the predictive factors for inadequate tissue yield in EUS-FNA (Table 3).

4. Discussion

GISTs are the most commonly identified intramural, submucosal mass in the upper GI tract. These masses are frequently found on endoscopy performed for other reasons, but patients may also present with abdominal pain, bleeding, or symptoms of mass effect [25]. It is well recognized that all GISTs have some degree of malignant potential [1, 2]. Even small localized GISTs may demonstrate malignant features on histologic examination or biologic behavior. However, the mucosal surface of SMT is usually normal, and the biopsy examination by conventional forceps at endoscopy was frequently negative, which showed the difficulty in achieving the material of SMT.
Table 2: Factors associated with the diagnostic yield of EUS-FNA.

| Factors          | All (n = 47) | Diagnostic (n = 35) | Nondiagnostic (n = 12) | P value |
|------------------|-------------|---------------------|------------------------|---------|
| Age (years old)  |             |                     |                        |         |
| 20–29            | 1 (2.1%)    | 0 (0%)              | 1 (8.3%)               |         |
| 30–39            | 3 (6.4%)    | 2 (5.7%)            | 2 (16.7%)              |         |
| 40–49            | 5 (10.6%)   | 8 (22.9%)           | 3 (25.0%)              |         |
| 50–59            | 11 (23.4%)  | 14 (40.0%)          | 3 (25.0%)              |         |
| 60–69            | 17 (36.2%)  | 6 (17.1%)           | 0 (0%)                 |         |
| 70–79            | 6 (12.8%)   | 6 (17.1%)           | 0 (0%)                 |         |
| 80–89            | 4 (8.5%)    | 4 (11.4%)           | 0 (0%)                 |         |
| Sex (M/F)        | 24/23       | 19/16               | 5/7                    | N.S.**  |
| Tumor location   |             |                     |                        |         |
| U                | 26 (55.3%)  | 22 (62.9%)          | 4 (33.3%)              | N.S.**  |
| M                | 15 (31.9%)  | 11 (31.4%)          | 4 (33.3%)              | N.S.**  |
| L                | 6 (12.8%)   | 2 (5.7%)            | 4 (33.3%)              | .013**   |
| Tumor size (mm)  |             |                     |                        |         |
| 10–19            | 5 (10.6%)   | 4 (11.4%)           | 1 (8.3%)               |         |
| 20–29            | 20 (42.6%)  | 14 (40%)            | 5 (41.7%)              |         |
| 30–39            | 14 (29.8%)  | 9 (25.7%)           | 5 (41.7%)              |         |
| 40–49            | 7 (14.9%)   | 6 (17.1%)           | 1 (8.3%)               |         |
| 50–                | 1 (2.1%)    | 1 (2.9%)            | 0 (0%)                 |         |
| Pattern of growth (No.[%]) |     |                     |                        |         |
| intragastric     | 34 (72.4%)  | 23 (65.7%)          | 11 (32.4%)             |         |
| extragastric     | 5 (10.6%)   | 5 (14.3%)           | 0 (0%)                 |         |
| mixed            | 8 (17.0%)   | 7 (20.0%)           | 1 (12.5%)              |         |
| Pattern of echography (No.[%]) |     |                     |                        |         |
| homo             | 20 (42.6%)  | 13 (37.1%)          | 7 (35.0%)              |         |
| hetero           | 27 (57.4%)  | 22 (62.9%)          | 5 (18.5%)              |         |

* Student t-test.  ** Chi-square test.

Table 3: Logistic regression analysis of factors associated with nondiagnostic yield of EUS-FNA.

| Univariate Analysis | Multivariate Analysis |
|---------------------|-----------------------|
|                      | Hazard Ratio (95% confidence interval) | P value | Hazard Ratio (95% confidence interval) | P value |
| Sex (Male)           | 0.564 (0.149–2.137)    | .564    | 11.91 (1.761–80.48) | .011    |
| Age (<60 years)      | 9.167 (1.720–48.85)    | .009    | 10.62 (1.290–87.42) | .028    |
| Location (Lower)     | 8.000 (1.238–51.69)    | .029    |                     |         |
| Tumor Size (>29 mm)  | 0.564 (0.149–2.137)    | .564    |                     |         |
| Pattern of growth (Intragastric) | 2.956 (0.732–11.93) | .128    |                     |         |
| Pattern of echography (Homo) | 5.739 (0.660–49.91) | .113    |                     |         |

The thresholds of age and tumor size were their average values.

EUS is effective for a diagnosis of these lesions. Lipomas, cysts and submucosal varices have typical features that allow accurate diagnosis based solely on the data gathered from endoscopy and EUS imaging [3, 4, 19]. Additionally, EUS-FNA is more effective for a diagnosis of SMT. In the study of 23 patients with GISTs, it is reported that EUS features alone had a diagnostic accuracy of 77% versus an accuracy of 91% obtained from immunohistochemical analysis from a FNA specimen [18].

Okubo et al. examined 18 patients with GIST undergoing both EUS-FNA and surgical resection and calculated a diagnostic yield and sensitivity of 78.0% (14/18) [22]. Akahoshi et al. studied 53 subepithelial gastric tumors. Diagnostic specimens were obtained in 42/51 (82%) patients [17]. In specifically investigated the use of EUS-FNA in evaluating intramural and extramural structures of the GI tract [24]. Ando et al. retrospectively examined 49 patients with submucosal tumors originating from the fourth sonographic layer. In 4 patients, specimens were inadequate for histopathologic diagnosis, giving a diagnostic yield of 91.8% (45/49) [18]. Okubo et al. examined 18 patients with GIST undergoing both EUS-FNA and surgical resection and calculated a diagnostic yield and sensitivity of 78.0% (14/18) [22]. Akahoshi et al. studied 53 subepithelial gastric tumors. Diagnostic specimens were obtained in 42/51 (82%) patients [17]. In
this study, the collection rate of adequate specimens from a gastric subepithelial hypoechoic tumor with continuity to proper muscle layer was 74.5%. No major complications were encountered. A reason for lower diagnostic yield in our study is that we defined, as diagnostic, EUS-FNA procedure only in a case of gaining a sufficient material for immunohistological diagnosis, which is essential for a diagnosis of GIST [1].

The predictive factors for inadequate EUS-FNA in gastric SMT were age and location in the stomach. Against our expectations, in younger patients, the rate of achieving adequate tissue yield in EUS-FNA for gastric SMT were age and location in the stomach. Against our study is that we defined, as diagnostic, EUS-FNA procedure only in a case of gaining a sufficient material for immunohistological diagnosis, which is essential for a diagnosis of GIST [1].

In conclusion, the diagnostic yield of EUS-FNA for the diagnosis of gastric SMT is 74.5%, and the factors associated with inadequate tissue yield in EUS-FNA for gastric SMT are younger age and location of lesion at L area in a stomach. Considering these factors may bring the improvement of accuracy in EUS-FNA.

Abbreviations

EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration biopsy
SMT: Submucosal tumor
GIST: Gastrointestinal stromal tumor
CI: Confidence interval

References

[1] J. Y. Blay, S. Bonvalot, P. Casali et al., “Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO,” Annals of Oncology, vol. 16, no. 4, pp. 566–578, 2005.
[2] M. Miettinen, L. H. Sobin, and J. Lasota, “Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up,” American Journal of Surgical Pathology, vol. 29, no. 1, pp. 52–68, 2005.
[3] K. Akahoshi, N. Harada, and H. Nawata, “The current state of endoscopic ultrasonography,” in Recent Research Developments in Radiology, S. G. Pandalai, Ed., pp. 1–22, Transworld Research Network, Kerala, India, 2003.
[4] M. F. Byrne and P. S. Jowell, “Gastrointestinal imaging: endoscopic ultrasonography,” Gastroenterology, vol. 122, no. 6, pp. 1631–1648, 2002.
[5] “Role of endoscopic ultrasonography. American Society for Gastrointestinal Endoscopy,” Gastrointestinal Endoscopy, vol. 52, pp. 852–859, 2000.
[6] R. A. Erickson, L. Sayage-Rabie, and A. Avots-Avotins, “Clinical utility of endoscopic ultrasound-guided fine needle aspiration,” Acta Cytologica, vol. 41, no. 6, pp. 1647–1653, 1997.
[7] F. G. Gress, R. H. Hawes, T. J. Savides, S. O. Ikenberry, and G. A. Lehman, “Endoscopic ultrasound-guided fine-needle aspiration biopsy using linear array and radial scanning endosonography,” Gastrointestinal Endoscopy, vol. 45, no. 3, pp. 234–250, 1997.
[8] D. O’Toole, L. Palazzo, R. Aroçarena et al., “Assessment of complications of EUS-guided fine-needle aspiration,” Gastrointestinal Endoscopy, vol. 53, no. 4, pp. 470–474, 2001.
[9] M. Kida, M. Araki, and K. Saijenji, “Present status and future perspectives of endoscopic ultrasonography-guided fine-needle aspiration,” in New Challenges in Gastrointestinal Endoscopy, H. Tajiri, M. Nakajima, and K. Yasuda, Eds., pp. 506–515, Springer, Tokyo, Japan, 2008.
[10] M. J. Wiersema, P. Vilmann, M. Giovannini, K. J. Chang, and L. M. Wiersema, “Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment,” Gastroenterology, vol. 112, no. 4, pp. 1087–1095, 1997.
[11] D. B. Williams, A. V. Sahai, L. Aabakken et al., “Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience,” Gut, vol. 44, no. 5, pp. 720–726, 1999.
[12] D. C. Chhieng, D. Jhala, N. Jhala et al., “Endoscopic ultrasound-guided fine-needle aspiration biopsy: a study of 103 cases,” Cancer, vol. 96, no. 4, pp. 232–239, 2002.
[13] M. A. Eloubeidi, D. Jhala, D. C. Chhieng et al., “Yield of endoscopic ultrasound guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma,” Cancer, vol. 99, no. 5, pp. 285–292, 2003.
[14] M. Giovannini, J. E. Seitz, G. Monges, H. Perrier, and I. Rabbia, “Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients,” Endoscopy, vol. 27, no. 2, pp. 171–177, 1995.
[15] H. J. Shen, S. Lahoti, and N. Sniege, “Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson Cancer Center experience,” Cancer, vol. 96, no. 3, pp. 174–180, 2002.
[16] M. J. Wiersema, L. M. Wiersema, K. Khusro, H. M. Cramer, and L. C. Tao, “Combined endosonography and fine-needle aspiration cytology in the evaluation of gastrointestinal lesions," Gastrointestinal Endoscopy, vol. 40, no. 2, pp. 199–206, 1994.
[17] K. Akahoshi, Y. Sumida, N. Matsui et al., “Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration,” World Journal of Gastroenterology, vol. 13, no. 14, pp. 2077–2082, 2007.
[18] N. Ando, H. Goto, Y. Niwa et al., “The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with
immunohistochemical analysis,” *Gastrointestinal Endoscopy*, vol. 55, no. 1, pp. 37–43, 2002.

[19] V. Arantes, R. Logroño, S. Faruqi, I. Ahmed, I. Waxman, and M. S. Bhutani, “Endoscopic sonographically guided fine-needle aspiration yield in submucosal tumors of the gastrointestinal tract,” *Journal of Ultrasound in Medicine*, vol. 23, no. 9, pp. 1141–1150, 2004.

[20] V. K. Chen and M. A. Eloubeidi, “Endoscopic ultrasound-guided fine-needle aspiration of intramural and extraintestinal mass lesions: diagnostic accuracy, complication assessment, and impact on management,” *Endoscopy*, vol. 37, no. 10, pp. 984–989, 2005.

[21] M. Gu, S. Ghafari, P. T. Nguyen, and F. Lin, “Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound-guided fine-needle aspiration biopsy: cytomorphologic and immunohistochemical study of 12 cases,” *Diagnostic Cytopathology*, vol. 25, no. 6, pp. 343–350, 2001.

[22] K. Okubo, K. Yamao, T. Nakamura et al., “Endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of gastrointestinal stromal tumors in the stomach,” *Journal of Gastroenterology*, vol. 39, no. 8, pp. 747–753, 2004.

[23] M. Polkowski, “Endoscopic ultrasound and endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of malignant submucosal tumors,” *Endoscopy*, vol. 37, no. 7, pp. 635–645, 2005.

[24] M. R. Vander Noot III, M. A. Eloubeidi, V. K. Chen et al., “Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy,” *Cancer*, vol. 102, no. 3, pp. 157–163, 2004.

[25] P. S. Sepe, B. Moparty, M. B. Pitman, J. R. Saltzman, and W. R. Brugge, “EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield,” *Gastrointestinal Endoscopy*, vol. 70, no. 2, pp. 254–261, 2009.